To examine the preventive effect of HSA-Trx on the pathological progression to NASH, HSA-Trx was administered intravenously at 200 nmol/kg twice a week for 2 weeks (HFD + HSA-Trx group) while the mice were being fed a HFD (Fig. S2A). The gene discussed is ALB; the disease is metabolic dysfunction-associated steatohepatitis.